Italia markets open in 30 minutes

Dow Jones
39.806,77
-196,82(-0,49%)
Nasdaq
16.794,88
+108,91(+0,65%)
Nikkei 225
38.946,93
-122,75(-0,31%)
EUR/USD
1,0866
+0,0005(+0,04%)
Bitcoin EUR
65.577,80
+3.831,83(+6,21%)
CMC Crypto 200
1.529,75
+41,21(+2,77%)

NBIX Jun 2024 130.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

1,0000

0,0000

(0,00%)

In data: 02:51PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat